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ABSTRACT: Dermal neurofibromas (dNFs) are benign
tumors of the peripheral nervous system typically associated
with Neurofibromatosis type 1 (NF1) patients. Genes
controlling the integrity of the DNA are likely to influence
the number of neurofibromas developed because dNFs are
caused by somatic mutational inactivation of the NF1 gene,
frequently evidenced by loss of heterozygosity (LOH).
We performed a comprehensive analysis of the prevalence
and mechanisms of LOH in dNFs. Our study included 518
dNFs from 113 patients. LOH was detected in 25% of the
dNFs (N5129). The most frequent mechanism causing
LOH was mitotic recombination, which was observed in
62% of LOH-tumors (N58 0 ) ,a n dw h i c hd o e sn o tr e d u c e
the number of NF1 gene copies. All events were generated
b yas i n g l ec r o s s o v e rl o c a t e db e t w e e nt h ec e n t r o m e r ea n d
the NF1 gene, resulting in isodisomy of 17q. LOH due to
the loss of the NF1 gene accounted for a 38% of dNFs with
LOH (N549), with deletions ranging in size from  80kb
to  8Mb within 17q. In one tumor we identified the first
example of a neurofibroma-associated second-hit type-2
NF1 deletion. Analysis of the prevalence of mechanisms
causing LOH in dNFs in individual patients (possibly under
genetic control) will elucidate whether there exist inter-
individual variation.
Hum Mutat 32:78–90, 2011. & 2010 Wiley-Liss, Inc.
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Introduction
One of the main challenges in the study of Neurofibromatosis
type 1 (NF1, MIM] 162200) is to have the ability to predict the
course of the disease. Prognostic markers can only be found if we
have a complete understanding of how the genetics and the
environment influence the different traits that compose the NF1
phenotype. One such trait is the development of dermal
neurofibromas (dNFs) in multiple numbers, benign tumors of
the peripheral nervous system.
The number of dNFs developed in NF1 patients is highly
variable, ranging from tens to thousands of tumors in a single
patient. The number of neurofibromas increases throughout life,
and their growth is highly influenced by the hormonal status of
the patient. Different studies meant to clarify the heritability of
NF1 traits have identified the existence of a strong genetic
component influencing the variable number of dNFs developed,
that seem to follow a polygenic model [Easton et al., 1993;
Sabbagh et al., 2009]. The role of the first-hit mutation at the NF1
locus (MIM] 613113; NG_009018.1) in this variation is still not
clear. Two types of constitutional NF1 mutations have been found
to influence neurofibroma number: Type-1 deletions (1.4-Mb
deletions with breakpoints located within NF1-REPs a and c) seem
to be associated with the early onset of a large number of dNFs
[Kayes et al., 1994; Wu et al., 1995] and the c.2970-2972 delAAT
mutation has been identified in patients with an absence of dNFs
[Upadhyaya et al., 2007]. However, these two types of constitu-
tional mutations only account for a small percentage of NF1
patients. Different studies also found a strong correlation between
first-, second-, and even third-degree relatives [Sabbagh et al.,
2009; Szudek et al., 2002], suggesting a role of the NF1 germline
mutation. However, it has also been observed that patients bearing
the same germline mutation, even affected patients from the same
family, can exhibit a very different number of dNFs [Ars et al.,
2000; Carey et al., 1979], although possible confounding factors,
such as patient’s age, need to be analyzed more carefully.
Neurofibromas are caused by the double inactivation of the
NF1 gene ([Sawada et al., 1996; Serra et al. 1997], and many other
works reviewed in [De Raedt et al., 2008]). Neurofibromas are
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(Barcelona), Spain. E-mail: eserra@imppc.orgcomposed of different cell types, but only Schwann cells bear a
double inactivation of the NF1 gene [Kluwe et al., 1999; Maertens
et al., 2006; Serra et al., 2000]. The ability to isolate pure
populations of NF1( / ) Schwann cells and analyze their genetic
material has demonstrated that the majority of somatic NF1
inactivations in dNFs are due to point mutations [Maertens et al.,
2006]. Because somatic mutations and neurofibroma-genesis are
causally linked, genes controlling DNA repair mechanisms are
good candidates for being modifiers of the number of dNFs
developed [Maertens et al., 2006; Serra et al., 2001a,b]. Furthermore,
it has been reported that in a significant percentage of dNFs
( 20%) somatic inactivation is evidenced by loss of heterozygosity
(LOH) (reviewed in [De Raedt et al., 2008, Serra et al., 2007;
Steinmann et al., 2009]), also including spinal neurofibromas
[Upadhyaya et al., 2009].
It has been known for a long time that different mechanisms are
responsible for LOH in tumors, such as mitotic recombination,
mechanisms that cause deletions of genetic material, or the loss of
a whole chromosome by nondisjunction with or without
reduplication [Cavenee et al., 1983; Tischfield, 1997]. Despite
the number of published articles describing the detection of
somatic LOH in the NF1 region in dNFs ([Colman et al., 1995]
and reviewed in [De Raedt et al., 2008]), there have only been a
few attempts to characterize the mechanisms underlying LOH in
dNFs [De Raedt et al., 2006a; Serra et al., 2001b; Steinmann et al.,
2009; Upadhyaya et al., 2008, 2009]. So far, a comprehensive study
of several hundred dNFs is missing. This should include the
evaluation of LOH frequency, the extent of the respective LOH
regions, and the identification of the number of copies of the NF1
gene. We performed such a study to investigate the mutation
mechanisms involved in the LOH of the NF1 gene in dNFs from
113 NF1 patients. These mechanisms are likely to be mainly
regulated by genes, which in a second step could be analyzed as
modifiers of the number of dNFs. We believe that having a clear
picture of the frequency of LOH in dNFs and understanding the
importance of the different mechanisms underlying NF1-LOH is
necessary for any further attempt to identify genes influencing
neurofibroma development.
Material and Methods
Patients and Neurofibromas
A total of 518 dermal neurofibromas (dNFs) from 113
Neurofibromatosis type 1 (NF1) patients were included in this
study. The patients were diagnosed according to standard
diagnostic criteria [DeBella et al., 2000]. All patients gave written
informed consent for the molecular studies performed. 318 of the
518 neurofibromas analyzed were already investigated for the
presence of LOH in a previous study [Serra et al., 2007]. Of these
318 tumors, 92 exhibited LOH. However, these 92 neurofibromas
required a more exhaustive analysis than previously performed in
order to determine the extent of LOH and the mutational
mechanism involved. Therefore, these 92 dNFs were reanalyzed in
this study using at least one of the techniques for detecting NF1
copy number described below. In addition to these 92 tumors, 200
so far uncharacterized dNFs were included in the present study
and investigated by the microsatellite multiplex PCR analysis.
Those dNFs among the 200 that exhibited LOH were also analyzed
using multiplex ligation-dependent probe amplification (MLPA)
or paralog ratio analysis (PRA) techniques (see below), and in
some of them (N519), SNP-array analysis was also performed.
Neurofibromas were completely removed after minor surgery,
undertaken by either a dermatologist or a surgeon. Surrounding
nonneurofibroma tissue was removed and tumors were cut into
different pieces. A piece of each tumor was preserved at  801C
until DNA was extracted. Whenever possible, remaining pieces of
each dNF were further cut, immersed in freezing solution [10%
DMSO, 90% fetal bovine serum (FBS)], and preserved in liquid
nitrogen until they were used to establish cell cultures.
Statistical Analysis
Confidence intervals (CIs) shown in Table 1 were calculated
using the Normal Approximation Method of the Binomial CI.
Taking data published by different groups in the literature (see,
i.e., [De Raedt et al., 2006a]), we assumed a general LOH
prevalence in neurofibromas from NF1 patients of 20%. Because
there is no information about the variation among NF1 patients
regarding this prevalence, we assumed a constant prevalence of
20% in order to assess the minimal number of dNFs to be tested
for each NF1 patient to estimate the LOH prevalence. As sampling
fraction is large, the binomial approximation is no longer
appropriate, and therefore we have used a finite population
correction term to adjust the variance of the normal distribution
to the more closely model of the hypergeometric density function
[Freund, 1992]. Under different scenarios of number of dNFs per
patient (see Supp. Fig. S1) we assessed that we need to analyze 10
dNFs to estimate the hypothesized prevalence with a precision of
20%. Increasing the number of neurofibromas analyzed would
improve precision, but it has also to be taken into account the
feasibility of analyzing a large number of neurofibromas from a
single patient, both for the patient and for the research team.
DNA Extraction
DNA from venous blood of the patients was isolated either by
the Wizard Genomic DNA purification kit (Promega, Madison,
WI) according to the manufacturer’s instructions or by the
‘‘salting out’’ method as described elsewhere [Miller et al., 1988].
This DNA was used as control or reference DNA in the LOH
analysis of tumors of the respective patients. Control DNA was
also obtained in some cases from the skin of patients (or derived
fibroblasts). DNA from skin, neurofibromas, Schwann cells, or
fibroblast cultures was extracted using the Gentra Puregene Kit
(Qiagen, Chatsworth, CA) following manufacturer’s instructions.
In all cases, purity and quality of DNA was assessed using a
nanodrop spectrophotometer and gel electrophoresis analysis. All
DNA samples were stored and preserved at 41C and at  801C.
LOH Analysis and Mutational Mechanism Characterization
In order to identify the type of somatic mutation generating
LOH, all dNFs were investigated by an extended analysis of
chromosome 17 microsatellites to determine LOH and its extent,
and also by MLPA and PRA to characterize the NF1 copy number.
In some dNFs, the characterization of LOH breakpoints at high
resolution and a global characterization of genome integrity were
assessed by SNP-array analysis. All genomic analyses were
performed using the NCBI36/hg18 assembly of the human genome.
Microsatellite Multiplex PCR (MMP) Analysis
We have developed an MMP assay that allows the simultaneous
amplification of 16 microsatellite markers (Supp. Table S1) in a
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markers in the p arm and 13 in the q arm) and 1 marker is located
in the q arm of chromosome 2. Primers were dye-labeled with
four different fluorophores, FAM (blue), NED (yellow), VIC
(green), and PET (red). We designed PCR products of different
sizes labeled with different colors in order to differentiate all of
them in a single genotyping run. MMP reaction was performed
using a Multiplex PCR kit from Qiagen in a 25-ml reaction with
100ng of DNA as follows: an initial cycle of denaturation at 951C
for 15min was followed by 25 cycles of denaturation at 941C,
annealing at 561C and extension at 721C, for 30sec, 3min, and
1.5min, respectively, and by a final cycle of 601C for 30min. We
checked that at 25 cycles the amplification reaction for all markers
was still at exponential phase (data not shown). A total of 1mlo f
PCR product was mixed with 9ml of highly deionized formamide
(Applied Biosystems, Bedford, MA) and 0.5ml of 500 LIZ
s Size
Standard. PCR fragments were separated by capillary electro-
phoresis on an ABI 3130xl Genetic Analyzer. Peak height values
were extracted using Peak Scanner software (Applied Biosystems).
In our hands, using peak height values was more accurate
than using peak areas, as shown by Paulson et al. [1999],
and recommended by the instrument’s manufacturer [Applied
Biosystems, Gene Mapper Software, Loss of Heterozygosity (LOH)
Analysis Getting Started Guide].
To assess the presence of LOH we performed an allelic
imbalance analysis, described by the expression Q
LOH [Hahn
et al., 1995] considering each microsatellite marker independently.
Q
LOH is calculated by dividing the allele ratio (the ratio between
the two alleles) of a given microsatellite from tumor DNA (tumor
peak height allele 1/tumor peak height allele 2) by the allele ratio
of the same microsatellite from control DNA (control peak height
allele 1/control peak height allele 2) [Solomon et al., 1987]. For
simplicity and comparative purposes we always have assigned peak
height allele 1 to the allele showing LOH. LOH was always assessed
by comparing pairs of control and tumor DNA from the same
patient. We considered presence of LOH in neurofibromas when
allele ratios comparing control and tumor samples (Q
LOH)
differed more than 20% (Q
LOHo0.8).
MLPA
We further analyzed the number of copies of the NF1 gene
present in DNA samples by using the MLPA technique designed
by MRC-Holland. Because the company is improving the assay
with time, different kits were used for the characterization of all
dNFs: Salsa MLPA Kit P122 versions P122, P122-B1, and P122-C1.
Briefly, this technique is based on a ligation-dependent probe
amplification of 12 to 28 probes (depending on the kit used)
encompassing the NF1 area together with 11 to 15 additional
control probes (also depending on the kit used). Probes differ in
size by means of spacers of different length that are probe-specific.
Only probes that are properly ligated can be amplified in the
subsequent PCR reaction. Once amplified, PCR fragments are
separated by capillary electrophoresis and peak intensities are
analyzed. For the Salsa MLPA Kit P122, PCR products of different
length (ranging from  100bp to  400bp, depending on the kit
used) were separated on an ABI 3130xl Genetic Analyzer. Peak
height values were extracted using Peak Scanner software (Applied
Biosystems) and were normalized as described by Wimmer et al.
[2006] for peak areas. Briefly, peak heights from individual probes
were divided by the sum of all peak heights of a given sample,
obtaining a relative value. Relative values of each probe were then
divided by the mean of the relative values of that probe obtained
only from control samples. After this normalization of peak
heights, it was possible to analyze the NF1 copy number. The
criteria used to assess the number of copies of the NF1 gene
present was the following: a value between 0.8 and 1.2 indicated
that two copies of the NF1 gene were present; a value lower than
0.8 implied that only one copy of the NF1 gene was present. In 13
cases, the presence of normal cells within neurofibromas bearing
LOH compromised these criteria (see Supp. Fig. S2). For this
reason in certain dNFs we had to assess NF1 copy number using
either the isolation of pure populations of neurofibroma-derived
Schwann cells, performing again the MLPA technique in their
isolated DNA, or by using only the Paralog Ratio Analaysis
technique.
PRA
This method was developed for the NF1 region by De Raedt
et al. [2006a] and determines the NF1 copy number status of a
sample DNA by comparing the peak height values of two PCR
products of a single amplification reaction. This PCR reaction
coamplifies a fragment of exon 22 present in the NF1 gene and the
same fragment bearing an insertion of 4bp from a single NF1
pseudogene located in chromosome 15. PRA reaction was
performed in a 10-ml final reaction with 80ng of DNA as follows:
an initial cycle of denaturation at 941C for 3min followed by 26
cycles of denaturation at 941C, annealing at 551C, and extension at
721C for 30sec each step. A final cycle of 721C for 7min was
performed.
We used a dosage quotient analysis comparing the ratios
between gene and pseudogene peaks obtained from a tumor and a
control sample from the same patient (in triplicate) and
established the presence of a deletion when the quotient of the
ratios obtained were below 0.8, that is, when the differences
between tumor and control DNAs were greater than 20%. With
this technique only deletions covering the region of exon 22 from
the NF1 gene can be detected. In addition, it has to be taken into
account that the NF1 pseudogene located in chromosome 15 is
placed in a copy number variation (CNV) region, and thus only
control and tumor pairs from the same patient can be compared
in the analysis, because both DNAs will contain the same number
of copies in the CNV region.
SNP-Array Analysis
To characterize LOH breakpoints of both deletions and mitotic
recombinations, as well as to explore other possible gross
alterations in the tumor genome, SNP-array analysis was
performed in 19 dNFs, using the Illumina Infinium technology
(Illumina, San Diego, CA). In all cases, pairs of control and
neurofibroma DNA were analyzed. Twelve dNFs were analyzed
using the Illumina 370-Quad beadchip ( 351,000 genotyping
SNPs,  9,300 located in the 17th chromosome), and seven dNFs
samples were investigated using the Human660W-Quad beadchip
( 592,000 genotyping SNPs,  15,600 located in the 17th
chromosome). DNA used for this type of analysis was of the
highest quality. DNA concentration, purity, and quality was first
assessed using a nanodrop spectrophotometer and gel electro-
phoresis analysis. For an accurate quantification of DNA
concentration, samples were further quantified using Quant-iT
PicoGreen reagent (Invitrogen, Carlsbad, CA). Raw data were
analyzed using the Illumina software GenomeStudio v2009.1 with
the Genotyping v1.1.9 module. The GenomeStudio program
provides two types of measurements. On the one hand, it provides
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reflects the allelic imbalance of each SNP. On the other hand, the
program generates the logR ratio metric, which reflects the
number of DNA copies. The logR ratio is a log-transformed ratio
of the measured SNP signal intensity by the expected intensity if
two copies of DNA were present. To calculate the percentage of
normal cells present in the tumor we used the same method as
Assie et al. [2008]. After obtaining the BAF value of the LOH
region, the percentage of cells exhibiting LOH was calculated using
the appropriate equation depending on the somatic event
generating LOH (deletion or recombination).
REP-Mediated Deletion Analysis
After performing Microsatellite Multiplex PCR Analysis and/or
MLPA analysis, a few neurofibromas were suspicious of bearing
deletions mediated by recombination between duplicated
sequences in the NF1 gene region (REP-mediated deletion).
In these cases, we performed several diagnostic PCR reactions, as
described by Steinmann et al. [2007], to identify somatic type-1 or
type-2 NF1 deletions with breakpoints either in the NF1-REPs or
in the SUZ12 sequences (see Fig. 1B).
Neurofibroma-Derived Schwann Cell Culture
Neurofibroma-derived Schwann cells bearing somatic muta-
tions (NF1 / ) were isolated as previously described [Serra et al.,
2000]. Briefly, neurofibroma pieces that were preserved in liquid
nitrogen were thawed and digested with collagenase and dispase
(Worthington, Lakewood, NJ) for 18hr at 371C. Subsequently,
tumors were mechanically dissociated and cell suspensions were
plated in six-well cultured plates coated with poly-L-Lysine
(Sigma, St. Louis, MO) and laminin (Invitrogen) in Schwann cell
medium (SCM) and maintained at 371C and 10% CO2. SCM is
DMEM (Gibco, Grand Island, NY) with 10% FBS, 500U/ml
penicillin/streptomycin (Gibco), 0.5mM 3-iso-butyl-1-methilxan-
tine (IBMX, Sigma), 2.5mg/ml insulin (Sigma), 10nM
b1-heregulin (R&D Systems, Minneapolis, MN), and 0.5mM
forskolin (Sigma). One day after plating, culture medium was
replaced by SCM without forskolin, for 2–3 additional days. This
process was repeated in cycles and cells were passaged as needed.
Schwann cell purity was assessed in each passage by performing an
S-100 staining as described [Serra et al., 2000]. Normally, after the
third passage, cell cultures contained 495% Schwann cells.
Results
Mutational Mechanisms Leading to LOH in dNFs
Our goal is to have a large population of Neurofibromatosis type
1 (NF1) patients with a molecular phenotypic characterization.
This consists of the estimation of LOH frequency implicated
in the generation of dNFs and the elucidation of the mechanisms
responsible for LOH. In doing so, we have obtained a clear
picture of LOH in dNFs and the frequencies of the mechanisms
responsible.
We have analyzed 518 dNFs obtained from 113 NF1 patients.
First we developed a rapid and cost-effective methodology to
obtain information on LOH presence and extent. Using this
technique (MMP analysis) we identified 129 dNFs exhibiting LOH
affecting the NF1 gene (Supp. Table S2). In a second step of the
analysis, we validated the presence of NF1 copies by performing
MLPA analysis. For many dNFs we also employed a PRA
developed by De Raedt et al. [2006a] to determine NF1 copy
number (see Materials and Methods). Finally, we investigated NF1
copy number, LOH extent, the percentage of cells bearing LOH
and deletions or duplications in other genomic regions in 19 dNFs
by genome-wide SNP-array analysis. Knowing the extent of the
LOH and the number of copies of the NF1 gene present in the
tumor enabled us to identify the mutation mechanism responsible
for each LOH detected (Table 1 and Supp. Table S2). dNFs are
composed of distinct cell types (Schwann cells, fibroblasts,
perineurial cells, etc.) in variable proportions, but only a group
of Schwann cells carry the somatic NF1 mutation. A high
percentage of non-LOH cells within neurofibromas can greatly
hamper the detection of a loss of 1 copy of the NF1 gene using
techniques such as MLPA or PRA. Therefore, we tested the limits
of detection of MLPA and PRA techniques for correctly finding a
deletion in the NF1 gene in the context of different proportions of
non-LOH cells within neurofibromas (Supp. Fig. S2). For doing
so, we performed serial admixtures of two DNAs: one carrying a
deletion in the NF1 gene and the other bearing two intact copies
of the gene, and analyzed these DNA admixtures using MMP,
MLPA, and PRA techniques. We then evaluated the limits of
detection of MLPA and PRA techniques for correctly finding an
NF1 deletion in relation to the Q
LOH values obtained using the
MMP analysis in the different admixtures (Supp. Fig. S2 and
Supp. Table S2). MLPA and PRA techniques were able to correctly
detect an NF1 deletion in neurofibromas with Q
LOH values
below 0.58 for MLPA, and Q
LOH values below 0.76 for PRA (Supp.
Fig. S2). None of the dNFs exhibiting LOH showed Q
LOH values
above 0.74. We were not able to analyze the NF1 copy number in
13 LOH-neurofibromas due to the lack of enough DNA material
after the presence of LOH being detected (see Supp. Table S2).
However, based on results obtained for the rest of LOH-tumors
(N5116) we assumed (and counted them as such) that for those
exhibiting LOH in the whole 17q arm, LOH was caused by
homologous recombination and for those with interstitial LOH,
loss of heterozygosity was caused by deletion.
LOH Affecting Copy Number
We identified 49 dNFs that exhibited the loss of 1 copy of the NF1
gene compared with their control tissue (see example in Fig. 1A,
T a b l e1 ,a n dS u p p .T a b l eS 2 ) .L O He x t e n s i o ni na l lc a s e sw a s
affecting only the NF1 gene or the NF1 gene and adjacent genomic
regions. The large distance between microsatellite markers and the
lack of heterozygosity in some of them hampered a fine mapping of
the precise extension of identified deletions. However, as is shown in
Figure 2A, deletions expanded roughly from  80kb to  8Mb.The
majority of interstitial deletions are presumed to be caused by DNA
double-strand breaks (DBS) and subsequent illegitimate joining of
DNA ends by homologous or nonhomologous end joining repair, or
by homologous recombination repair [Bishop and Schiestl, 2003;
Table 1. Global View of LOH in Neurofibromas
No. of patients 113
dNFs analyzed 518
dNFs with LOH 129 (49 deletions/80 MRs)
% LOH tumors/total tumors 24.9
% LOH-deletion/total tumors (95% CI) 9.4 (6.8–11.9)
% LOH-recombination/total tumors (95% CI) 15.4 (12.3–18.5)
% LOH-deletion/LOH-tumors (95% CI) 38 (29.7–46.3)
% LOH-recombination/LOH-tumors (95% CI) 62 (53.7–70.3)
LOH, loss of heterozygosity; CI, confidence interval; dNF, dermal neurofibroma; MR,
mitotic recombination.
HUMAN MUTATION, Vol. 32, No. 1, 78–90, 2011 81Kohno and Yokota, 2006]. The structure of breakpoint junctions
helps with the identification of the repair mechanism used, as the
breakpoint can retain sequence signatures indicative of the
mechanism involved in the repair. Characterizing breakpoints and
understanding the exact mechanisms generating deletions was
beyond the scope of this work. However, we used SNP-array
Figure 1. Mechanisms leading to LOH in neurofibromas. A: Mechanisms generating deletions. In all cases Microsatellite Multiplex PCR
(MMP) analysis evidenced LOH in the NF1 gene (NG_009018.1) and normally also in 50 and 30 regions adjacent to it. MLPA detected only one
copy of the NF1 gene. SNP-array analysis detected LOH (four-band pattern in the B allele frequency plot) and one copy of the NF1 gene (LogR
ratio o0). B: Nonallelic homologous recombination causing deletion. MMP detected LOH involving the NF1 gene and adjacent regions,
apparently not going further 50 or 30 of the NF1-REPs. A table summarizing the PCR conditions used for detecting the deletion breakpoint is
depicted. Breakpoint localized in SUZ12 intron 4. C: Homologous recombination. MMP evidenced LOH of almost all 17q chromosome. MLPA
detected two copies of the NF1 gene and the entire region analyzed. SNP-array detected LOH (four-band pattern in the B allele frequency plot)
from the centromere to the end of the chromosome (17q telomere) and the presence of two copies (LogR ratio50) of the entire chromosome
17q. MMP (35no LOH; dashed circles5noninformative,  5LOH). MLPA (Values between 0.8 and 1.25two copies. Values o0.85one copy).
SNP-array: B allele frequency plot (0.55heterozygote; 0 or 15homozygote, other intermediate values5allelic imbalance); LogR ratio (05two
copies; values o05one copy). [Color figures can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Figure 2. Deletion breakpoint analysis. A: Breakpoint analysis by Multiplex Microsatellite PCR (MMP) and by MLPA analysis. B: Deletion
breakpoint mapping refinement by SNP-array. Solid black bar: deletion mapped by either MMP (A, B), by MLPA (A), or SNP-array (B); dashed
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carrying deletions affecting the NF1 gene, and in these cases we were
also able to narrow down the deletion breakpoints (Fig. 2B). With
this analysis we confirmed that deletions do not seem to involve
DNA regions greater than  8Mb. In the future it will be possible to
further analyze and finally sequence the deletion breakpoints of
these dNFs.
After performing MMP analysis and/or MLPA analysis, we
observed that in two neurofibromas (P004-7N, P082-1N) the
deletion breakpoints were located very close to the low-copy
repeats (NF1-REPs and the SUZ12 sequences) flanking the NF1
gene region. In both patients a germline point mutation was
already identified. To investigate whether the somatic deletions in
these two tumors were mediated by nonallelic homologous
recombination (NAHR) between these low-copy repeats, we
performed PCR reactions [Steinmann et al., 2007] to detect the
breakpoints of previously identified NF1 microdeletions in
patients with constitutional type-1 or mosaic type-2 deletions
[De Raedt et al., 2006b; Steinmann et al., 2007]. We identified one
dNF (P082-1N) (Fig. 1B) that carried a type-2 deletion. This type
of NF1 deletion is caused by nonallelic homologous recombination
between the SUZ12 gene and its pseudogene, which are located
adjacent to the NF1-REPs. First-hit type-2 NF1 microdeletions are
identified in mosaic NF1 patients, and thus they are assumed to
occur during early fetal development [Kehrer-Sawatzki and
Cooper, 2008].
In 13 dNFs we detected LOH affecting only the NF1 gene and
flanking regions (Fig. 3A) (what in principle suggested the
presence of an interstitial deletion) but when applying MLPA
analysis, the same tumors were apparently exhibiting two copies of
the NF1 gene (Fig. 3B). These results opened up the possibility of
new mechanisms causing LOH in dNFs, such as homologous
recombination with two crossovers, one at 50 and the other at 30 of
the NF1 gene.
However, SNP-array analyses of several of these neurofibromas
revealed that the percentage of non-LOH cells was quite high
(Fig. 3C), an indication that was also supported by the high Q
LOH
values obtained (e.g., Q
LOH50.62 for P079-1N, Supp. Table S2).
In the cases where Q
LOH values were higher than 0.58, MLPA
technique was not adequate for assessing the number of NF1
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Figure 3. The presence of normal cells in neurofibromas affects the NF1-copy number detection by MLPA. A: MMP analysis of tumor P079-
1N (see legend of Fig. 1 for nomenclature); B: MLPA of P079-1N detected two copies of the NF1 gene; C: SNP-array analysis evidenced a high
proportion ( 70%) of normal cells within tumor P079-1N; D: MLPA of P079-1N NF1( / ) Schwann cell culture detected one copy of the NF1
gene. E: Purity of the culture was evidenced by MMP analysis, comparing control, tumor, and SC culture. A total loss of one allele was detected
in the SC culture. MLPA (values between 0.8 and 1.25two copies. Values o0.85one copy). [Color figures can be viewed in the online issue,
which is available at wileyonlinelibrary.com.]
84 HUMAN MUTATION, Vol. 32, No. 1, 78–90, 2011copies (Supp. Fig. S2). Accordingly, we decided to perform
additional analysis. For two neurofibromas we were able to culture
pure populations of dNF-derived NF1( / ) Schwann cells
(Fig. 3E). In these two cases (P079-1N, P062-4N) when DNA
isolated from pure NF1( / ) Schwann cell populations was re-
analyzed by MLPA, the loss of one copy of the NF1 gene was
detected (Fig. 3D). Thus, LOH detected in these two tumors was
indeed caused by deletions. In 7 of the remaining 11 dNFs we were
able to assess the presence of only one copy of the NF1 gene by
applying either PRA analysis or/and SNP-array analysis. For the
remaining four neurofibromas we were not able to determine the
NF1 copy number due to the lack of DNA (Supp. Table S2).
Copy Neutral LOH Mechanisms
We identified 80 dNFs exhibiting LOH that started somewhere
between the centromere of chromosome 17 and the NF1 gene and
extended to the 17q telomere (Fig. 1C, Table 1, Supp. Table S2).
Thus, the LOH detected in these tumors involved almost the
entire long arm of chromosome 17. Importantly, two copies of the
17q arms were present in these tumors, as well as the two copies of
the NF1 gene carrying the constitutional mutation [Serra et al.,
2001b]. The mechanism generating LOH in these tumors was
homologous recombination (mitotic recombination) with a
unique crossover between the centromere and the NF1 gene,
generating isodisomy from the crossover region up to the 17q
telomere (as evidenced by SNP-array analysis) (Fig. 1C). This
mutational mechanism was found to be the cause of  62% of all
LOH events detected in dNFs (Table 1). Again, as for the fine
mapping of deletion breakpoints, the use of microsatellites did not
facilitate a precise location of recombination breakpoints (or
crossovers) (Fig. 4A). Nevertheless, in eight dNFs we were able to
locate the crossover region at a higher resolution using SNP-array
analysis (Fig. 4B). We found that in two dNFs the crossover was
centromeric to the D17S783 marker, clearly located closer than
1Mb from the centromere. However, in addition, there were a fair
number of dNFs (N529) homozygous (noninformative) for
marker D17S783, for which the crossover could also be located
close to the centromere. We found that this was the case of tumors
P102-18N and P103-1N (Fig. 4B). For five dNFs there were no
informative 17p microsatellite markers (three from the same
patient). We were not able to rule out the possibility of a loss of
the complete chromosome 17 with an endoreduplication of the
remaining one, in these cases. There were also a significant
number of dNFs for which the crossover was apparently located
closer than 1Mb from the NF1 gene. In eight dNFs the breakpoint
was clearly located between marker D17S1294 and the NF1 gene.
After performing SNP-array analysis we found that in tumor
P103-5N the crossover was located in a region of 260–400kb close
to the NF1 transcription start site. However, in many dNFs the
crossover seemed to occur in a region equidistant from the
centromere and the NF1 gene (see Fig. 4B).
Other Genomic Alterations in Neurofibromas
We performed SNP-array analysis in 19 dNFs to obtain a higher
resolution on the LOH status of the NF1 locus and in addition to
scan their whole genome for the presence of additional copy
number changes or copy neutral LOH. Seventeen dNFs exhibited
no copy number changes or LOH elsewhere in the genome except
for the 17q alteration involving the NF1 gene. We identified two
dNFs containing a large deletion: one located in chromosome
2q24.2–q31.1 (P090-3N) of about 15.3Mb and the other in
chromosome 3q11.2–q22.1 (P072-1N) of about 39.8Mb (Fig. 5).
None of the deletions were present in the matching control DNAs,
evidencing somatic events. In tumor P090-3N chromosome 2 and
17q-NF1 deletions were present in the same proportion of cells
( 49%), suggesting that both alterations affected the same cells.
In contrast, in tumor P072-1N, the 17q-NF1 deletion was present
in 49% of the cells while the chromosome 3q deletion was only
present in  37% of the cells. This finding could reflect that either
the 3q deletion occurred later during tumor development or that
both deletions together do not confer a proliferation advantage to
the cell.
Variation in Neurofibroma-LOH Frequencies in Distinct
NF1 Patients
Our final objective, in addition to have a more definitive picture
of neurofibroma-LOH, was to have a cohort of NF1 patients with
information about the phenotype at the molecular level,
consisting of the characterization of LOH frequencies in dNFs
and also the mechanisms responsible for the identified LOH. We
calculated the minimal amount of dNFs needed to estimate the
LOH prevalence in each patient, under the hypothesis of a finite
number of dNFs, using different scenarios of precision and with a
95% confidence level (see Materials and Methods). For patients
with 50 to 1,000 dNFs, we calculated that at least 10 dNFs had to
be analyzed to estimate the LOH prevalence in these patients with
a precision of 20% (see Supp. Fig. S1). Among the 113 patients, in
13 ( 10%) we studied at least 10 dNFs (Table 2). Although our
results are still preliminary, the prevalence of LOH in dNFs in this
group of 13 patients ranges from less than 10 to 50% or even
higher. We also focused in the mechanism generating LOH. Most
patients had dNFs with LOH caused by either deletions or
recombination leading to copy neutral LOH. However, there were
also patients with a clear dominant LOH mechanism. For
example, dNFs of patient P082 exhibited mainly LOH caused by
deletions, whereas dNFs of patients P022 and P078 had LOH
primarily due to mitotic recombination (Table 2), regardless of
LOH prevalence in dNFs. Two patients bearing the same germline
NF1 mutation (P062 and P082) exhibited a quite different
prevalence of LOH in dNFs and a different preference of LOH-
generating mechanism (Table 2).
Discussion
A huge variability concerning the number of dNFs is observed
in patients with NF1. Although genetic modifiers, unlinked to the
NF1 locus, are assumed to contribute to the variable number of
dNFs [Easton et al., 1993; Sabbagh et al., 2009], the nature of these
genes or genetic mechanisms are still unknown. With the long-
term objective of identifying genes influencing the variation in
number of dNFs, in the present study we have determined the
prevalence of mechanisms generating LOH responsible for the
inactivation of the NF1 gene in these tumors. Our working
hypothesis is that genes influencing the rate and efficiency of these
mechanisms are key factors of neurofibroma development,
because somatic inactivation of the NF1 gene is a necessary and
limiting step in dNF development. We focused our attention to
those DNA repair systems involved in mechanisms leading to
LOH, especially homologous recombination, but certainly other
DNA repair mechanisms, will also be involved. We analyzed 518
dNFs from 113 patients and obtained the most comprehensive
picture of LOH prevalence in dNFs published so far and also a
HUMAN MUTATION, Vol. 32, No. 1, 78–90, 2011 85comprehensive overview of the mechanisms underlying these
LOH events.
We identified LOH in 25% of the dNFs studied (129/518). This
number is in agreement with the average of the previously
reported LOH prevalence of dNFs ( 20%) (reviewed in [Serra
et al., 2007; Steinmann et al., 2009]). It has been shown that NF1
microdeletion patients do not exhibit LOH as a second hit in
dermal neurofibromas [De Raedt et al., 2006a] by analyzing SNPs
outside the microdeletion region. In the present study only 6 out
of 518 neurofibromas (1.1%) belonged to NF1-microdeletion
patients (N54). We have not identified any LOH in these six
neurofibromas, confirming previous observations. We found that
LOH was basically generated by two types of mechanisms:
interstitial deletions and mitotic recombination. Approximately
38% of all LOH events detected were caused by deletions in 17q,
whereas 62% were caused by mitotic recombination with a single
crossover between the centromere and the NF1 gene, and reducing
the constitutional NF1 mutation to homozygosity. This finding
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Figure 4. Mitotic recombination crossover mapping. A: Crossover analysis by Multiplex Microsatellite PCR (MMP). B: Mapping refinement by
SNP-array compared to MMP. Solid black bar: uniparental isodisomy (B); dashed line: uncertain region; black circle: no uniparental isodisomy.
HR, Homologous recombination. [Color figures can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
86 HUMAN MUTATION, Vol. 32, No. 1, 78–90, 2011highlights the importance of copy neutral LOH generated by
mitotic recombination regarding the inactivation of the NF1 gene
in the peripheral nervous system. Taking into account that we
detected LOH in 25% of all dNFs, mitotic recombination could be
responsible of  15% of all somatic NF1 inactivation in dNFs.
Furthermore, our present study in conjunction with the one
previously performed by Steinmann et al. [2009] on plexiform
neurofibromas, indicates that the prevalence of LOH and the
mechanisms underlying LOH in dermal and plexiform neurofi-
bromas are fairly similar, although both tumors differ consider-
ably concerning their position, growth pattern and potential for
malignant transformation.
In addition to the analysis of a global LOH prevalence and the
underlying mechanisms in all dNFs studied, we also considered
the prevalence and nature of LOH events in dNFs from single NF1
patients. To start describing the individual LOH prevalence, we
summarized in Table 2 data from 14 patients from whom 10 or
more dNFs were analyzed (except for 1 patient), the minimal
number of dNFs per patient required. We consider that a larger
number of patients with 10 or more dNFs analyzed need to be
collected to make any assessment about the interindividual
variation regarding dNF-LOH prevalence and underlying events,
with the adequate statistical power. However, considering just a
description of the results, in several patients we observed a major
LOH-causing mechanism (either deletion or mitotic recombina-
tion). In the case there is a significant variation in individual LOH
prevalence among NF1 patients, for those individuals with a high
dNF-LOH prevalence together with a predominant LOH-mechan-
ism, there exist the possibility that genes controlling the frequency
of such mechanisms in vivo act as modifiers of the number of
neurofibromas. For mitotic recombination these results would be
in concordance with results obtained regarding the interindividual
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Figure 5. SNP-array analysis of samples P090-3N and P072-1N compared to their respective controls. A: Detection of deletions in 2q and the
NF1 region in tumor P090-3N; B: Detection of deletions in 3q and the NF1 region in tumor P072-1N. Deletions were evidenced by a four-band
pattern in the B allele frequency plot and a LogR ratioo0.
HUMAN MUTATION, Vol. 32, No. 1, 78–90, 2011 87variation in mitotic recombination rates detected when analyzing
the HLA-A locus in lymphocytes [Holt et al., 1999].
Most homologous recombination crossovers underlying LOH
in neurofibromas were found to be located between the
centromere and the NF1 gene (Fig. 4). However, in a significant
number of dNFs the LOH causing crossover events was likely to be
close to the centromere; this would implicate chromosome and
specifically centromere dynamics as the generators of double-
strand breaks. On the other hand, the recombination crossovers of
a few dNFs could be located really close to the NF1 gene, even
closer than in tumor P103-5N (Fig. 4B). For these cases it could be
speculated that transcription-coupled repair may be implicated in
the generation of crossovers. Mitotic recombination generating
uniparental isodisomy in 17q has also been reported as the cause
of NF1 inactivation in NF1-associated myeloid malignancies
[Stephens et al., 2006]. The authors postulated that in some
leukemias isodisomies were generated by a double recombination
with crossovers located in the centromere and the telomere of 17th
chromosome. This mechanism, however, is unlikely to frequently
cause LOH in dNFs. In all dNFs with LOH caused by mitotic
recombination and analyzed by SNP-arrays (see Fig. 1C as an
example), 17q isodisomy extended to the 17q telomere, with only
one recombination crossover located between the centromere and
the NF1 gene. Finally, for five dNFs (three from the same patient)
there were no informative 17p microsatellite markers raising the
possibility of a loss of the complete chromosome 17 with an
endoreduplication of the remaining chromosome. However, we
believe this is not a very plausible possibility because this type of
event has only been reported in the literature once for a dNF.
Somatic deletions in 17q were observed in 38% of the dNFs
showing LOH (9.4% of the total number of dNFs included in our
study). Deletions expanded roughly from  80kb to  8Mb.
However, the large distance between microsatellite markers and
the lack of heterozygosity in some cases make us to believe that
MMP analysis is underestimating deletions equal or smaller to
 100kb. Elucidating the precise mechanism causing these
interstitial deletions is an arduous task because it requires a
proper characterization and sequencing of the deletion break-
points. A higher resolution SNP-array analysis of these tumors
could facilitate this work and help to dissect all the various
possible mechanisms involved in generating these deletions.
Importantly, we identified one neurofibroma (P082-1N)
bearing a type-2 NF1 deletion, caused by a nonallelic homologous
recombination (NAHR) between the SUZ12 gene and its
pseudogene, which are both located adjacent to the NF1 low
copy repeats. The breakpoint of the somatic deletion in tumor
P082-1N was located in the SUZ12 intron 4. This type of deletion
has been also identified in patients with somatic mosaicism, with
some cells carrying the deletion and others not carrying it. In these
patients, however, the type-2 deletion was the first-hit mutation,
which probably occurred during early embryonic development
because it was found at a high percentage in blood lymphocytes
[Steinmann et al., 2007]. The somatic type-2 deletion identified in
tumor P082-1N in this study has to be considered as a second-hit
mutation that leads to the loss of the wild-type NF1 allele. Not all
type 2 microdeletions can be PCR amplified by a primer set for
common breakpoints, and thus we cannot rule out the involve-
ment of NF1-REPs or the SUZ12 sequences in the deletion
identified in tumor P004-7N, because MLPA results were
consistent with this type of deletion. Although it is clearly an
infrequent mechanism, somatic NAHR involving the SUZ 12
sequences indeed leads to NF1 loss in dNFs.
There have been different attempts to characterize the whole
genome of dNFs in order to search for additional genetic
alterations that could help to find other genes implicated in
dNF development. However, although there is some disparity in
different studies, reports using different methodologies, such us
comparative genomic hybridisztion (CGH) [Mechtersheimer
et al., 1999], cytogenetic karyotyping of dermal neurofibroma-
derived Schwann cells [Wallace et al., 2000], cytogenetic
karyotyping of short term neurofibroma cultures [Mertens
et al., 2000], array-CGH [Mantripragada et al., 2008, 2009], Eric
Legius, personal communication), and SNP-array analyses (Nancy
Ratner and the NF1 Microarray Consortium, unpublished
results), indicated a paucity of recurrent gross alterations in
dNFs. SNP-array analysis of 19 dNFs allowed us to have a better
idea of the global genome integrity of dNFs beyond the NF1
region. We identified two dNFs with large deletions in two distinct
chromosomal regions, one in 2q24.2–q31.1 (observed in tumor
P090-3N) and the other in 3q11.2–q22.1 (in tumor P072-1N).
These findings are consistent with the most recent findings
obtained using array-CGH, where no gross alterations or just a
few and sporadic copy number alterations were identified in
dermal neurofibromas [Mantripragada et al., 2008, 2009]. The
genomic alterations found in the present study appeared to be
random events, as deduced from their low frequency and the lack
Table 2. Interindividual Variation in Neurofibroma-LOH and the Mechanisms Responsible
% LOH-deletion % LOH-MR
Germline mutation
Patient dNFs analyzed dNFs with LOH % LOH (no. dNFs) (no. dNFs) DNA level Protein level
P011 14 5 35.7 20 (1) 80 (4) c.3826C4T p.Arg1276X
P020 14 2 14.3 0 100 (2) c.2041C4T p.Arg681X
P022 19 9 47.3 22.2 (2) 77.8 (7) c.1756_1759delACTA p.Thr586fsX18
P023 86 14 16.2 35.7 (5) 64.3 (9) c.3525_3526delAA p.Arg1176fsX18
P027 14 1 7.1 0 100 (1) c.6226delG p.Ala2076fsX14
P052 11 1 9.1 100 (1) 0 c.6791_6792dupA [p.Tyr2264X; p.Ala2253_Lys2286del]
P055 11 1 9.1 0 100 (1) c.5710G4T p.Glu1904X
P062 16 6 37.5 33.3 (2) 66.7 (4) c.910C4T [p.Arg304X; p.Lys297_Lys354del]
P078 48 6 12.5 0 100 (6) c.4537C4T p.Arg1513X
P082 9 5 55.5 100 (5) 0 c.910C4T [p.Arg304X; p.Lys297_Lys354del]
P084 10 2 20 0 100 (2) c.4572C4G p.Tyr1524X
P102 16 5 31.2 40 (2) 60 (3) c.5242C4T p.Arg1748X
P103 21 10 47.6 30 (3) 70 (7) c.2338A4C p.Thr780X
P104 11 3 27.3 0 100 (3) c.4308G4T p.Glu1436X
LOH, loss of heterozygosity; dNF, dermal neurofibroma; MR, mitotic recombination. Mutation numbering follows journal guidelines, with 11 as the A of the initiation codon
(codon 1) and based on NF1 GenBank NM_000267.3.
88 HUMAN MUTATION, Vol. 32, No. 1, 78–90, 2011of recurrence among different dNFs. It is unlikely that these
somatic events are necessary for neurofibroma growth. Thus, the
majority of discrete dermal neurofibromas do not frequently
exhibit additional gross alteration in other genomic regions except
for 17q. However, it remains to be investigated whether mutations
such as small deletions, small insertions, and point mutations in
genes or regulatory regions exist that would contribute to dNF
growth. Nevertheless, the lack of any recurrent gross alteration in
the genome of dNFs favors the idea that, genetically, NF1
inactivation in neurofibroma-initiating cells (precursor cells that
have the capacity to differentiate into Schwann cells) might be
sufficient for dermal neurofibromas to develop (in an NF1 (1/ )
background). Recent results in a dermal neurofibroma mice
model favors this view [Le et al., 2009].
The presence of instability in the analysis of microsatellite
markers (MSI) in neurofibromas has been raised several times
(see. i.e., [Ottini et al., 1995], or more recently [Thomas et al.,
2010]). We have not found MSI in any of the 518 neurofibromas
belonging to 113 patients regardless of their tumor burden,
despite the fact that several of the markers used in the MMP
analysis were previously tested to be useful for detecting MSI in
pairs of colorectal tumors with MSI [Serra et al., 1997].
Taken together, our work provides a comprehensive overview of
the somatic mutational mechanisms generating LOH in benign
neurofibromas. This has implications when identifying possible
modifiers that influence the rate and nature of somatic events
leading to the inactivation of the NF1 gene. These modifiers in
turn could prove to influence the number of dNFs developed in
NF1 patients.
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